Cargando…
Statin use and risk of colorectal cancer in patients with inflammatory bowel disease
BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we id...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474364/ https://www.ncbi.nlm.nih.gov/pubmed/37662517 http://dx.doi.org/10.1016/j.eclinm.2023.102182 |
_version_ | 1785100475857633280 |
---|---|
author | Sun, Jiangwei Halfvarson, Jonas Bergman, David Ebrahimi, Fahim Roelstraete, Bjorn Lochhead, Paul Song, Mingyang Olén, Ola Ludvigsson, Jonas F. |
author_facet | Sun, Jiangwei Halfvarson, Jonas Bergman, David Ebrahimi, Fahim Roelstraete, Bjorn Lochhead, Paul Song, Mingyang Olén, Ola Ludvigsson, Jonas F. |
author_sort | Sun, Jiangwei |
collection | PubMed |
description | BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and followed until December 2019. Primary outcome was incident CRC. Secondary outcomes were CRC-related mortality and all-cause mortality. Cox regression estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). FINDINGS: During a median follow-up of 5.6 years, 70 statin users (incidence rate (IR): 21.2 per 10,000 person-years) versus 90 non-statin users (IR: 29.2) were diagnosed with incident CRC (rate difference (RD), −8.0 (95% CIs: −15.8 to −0.2 per 10,000 person-years); aHR = 0.76 (95% CIs: 0.61 to 0.96)). The benefit for incident CRC was duration-dependent in a nested case-control design: as compared to short-term use (30 days to <1 year), the adjusted odd ratios were 0.59 (0.25 to 1.43) for 1 to <2 years of use, 0.46 (0.21 to 0.98) for 2 to <5 years of use, and 0.38 (0.16 to 0.86) for ≥5 years of use (P(for tread) = 0.016). Compared with non-statin users, statin users also had a decreased risk for CRC-related mortality (IR: 6.0 vs. 11.9; RD, −5.9 (−10.5 to −1.2); aHR, 0.56 (0.37 to 0.83)) and all-cause mortality (IR: 156.4 vs. 231.4; RD, −75.0 (−96.6 to −53.4); aHR, 0.63 (0.57 to 0.69)). INTERPRETATION: Statin use was associated with a lower risk of incident CRC, CRC-related mortality, and all-cause mortality. The benefit for incident CRC was duration-dependent, with a significantly lower risk after ≥2 years of statin use. FUNDING: This research was supported by 10.13039/501100006636Forte (i.e., the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare). |
format | Online Article Text |
id | pubmed-10474364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104743642023-09-03 Statin use and risk of colorectal cancer in patients with inflammatory bowel disease Sun, Jiangwei Halfvarson, Jonas Bergman, David Ebrahimi, Fahim Roelstraete, Bjorn Lochhead, Paul Song, Mingyang Olén, Ola Ludvigsson, Jonas F. eClinicalMedicine Articles BACKGROUND: Statin use has been linked to a reduced risk of advanced colorectal adenomas, but its association with colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) - a high risk population for CRC - remains inconclusive. METHODS: From a nationwide IBD cohort in Sweden, we identified 5273 statin users and 5273 non-statin users (1:1 propensity score matching) from July 2006 to December 2018. Statin use was defined as the first filled prescription for ≥30 cumulative defined daily doses and followed until December 2019. Primary outcome was incident CRC. Secondary outcomes were CRC-related mortality and all-cause mortality. Cox regression estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). FINDINGS: During a median follow-up of 5.6 years, 70 statin users (incidence rate (IR): 21.2 per 10,000 person-years) versus 90 non-statin users (IR: 29.2) were diagnosed with incident CRC (rate difference (RD), −8.0 (95% CIs: −15.8 to −0.2 per 10,000 person-years); aHR = 0.76 (95% CIs: 0.61 to 0.96)). The benefit for incident CRC was duration-dependent in a nested case-control design: as compared to short-term use (30 days to <1 year), the adjusted odd ratios were 0.59 (0.25 to 1.43) for 1 to <2 years of use, 0.46 (0.21 to 0.98) for 2 to <5 years of use, and 0.38 (0.16 to 0.86) for ≥5 years of use (P(for tread) = 0.016). Compared with non-statin users, statin users also had a decreased risk for CRC-related mortality (IR: 6.0 vs. 11.9; RD, −5.9 (−10.5 to −1.2); aHR, 0.56 (0.37 to 0.83)) and all-cause mortality (IR: 156.4 vs. 231.4; RD, −75.0 (−96.6 to −53.4); aHR, 0.63 (0.57 to 0.69)). INTERPRETATION: Statin use was associated with a lower risk of incident CRC, CRC-related mortality, and all-cause mortality. The benefit for incident CRC was duration-dependent, with a significantly lower risk after ≥2 years of statin use. FUNDING: This research was supported by 10.13039/501100006636Forte (i.e., the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare). Elsevier 2023-08-24 /pmc/articles/PMC10474364/ /pubmed/37662517 http://dx.doi.org/10.1016/j.eclinm.2023.102182 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Sun, Jiangwei Halfvarson, Jonas Bergman, David Ebrahimi, Fahim Roelstraete, Bjorn Lochhead, Paul Song, Mingyang Olén, Ola Ludvigsson, Jonas F. Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title_full | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title_fullStr | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title_full_unstemmed | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title_short | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
title_sort | statin use and risk of colorectal cancer in patients with inflammatory bowel disease |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474364/ https://www.ncbi.nlm.nih.gov/pubmed/37662517 http://dx.doi.org/10.1016/j.eclinm.2023.102182 |
work_keys_str_mv | AT sunjiangwei statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT halfvarsonjonas statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT bergmandavid statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT ebrahimifahim statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT roelstraetebjorn statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT lochheadpaul statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT songmingyang statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT olenola statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease AT ludvigssonjonasf statinuseandriskofcolorectalcancerinpatientswithinflammatoryboweldisease |